Text Size

Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects

This study has been completed.
Sponsor:
Collaborators:
Albert Einstein College of Medicine of Yeshiva University
Montefiore Medical Center
Information provided by (Responsible Party):
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT00706550
First received: June 24, 2008
Last updated: February 20, 2013
Last verified: February 2013
History of Changes

June 24, 2008
February 20, 2013
October 2008
September 2011   (final data collection date for primary outcome measure)
Antibody levels [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00706550 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects
Immune Responses to Pneumococcal Vaccination Among HIV-Infected Subjects

The purpose of this study is to evaluate the best timing for administering pneumococcal vaccine (PV) to HIV-infected adults that have CD4 cell counts of more than 200 and are not yet receiving combination antiretroviral treatment (ART). Participants in this study will be assigned by chance to receive vaccination with PV prior to starting ART or after at least 6 months of ART. Antibody levels to components of the PV will be measured at 6 months and 12 months after vaccination. The results will tell us if patients that receive PV after 6 months of ART have better response to the vaccine than those that get vaccinated prior to treatment.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Prevention
HIV Infections
  • Biological: 23-valent pneumococcal polysaccharide vaccine
    Currently commercially available pneumococcal polysaccharide vaccine
  • Biological: Placebo
    Arm 2 will receive placebo prior to starting antiretroviral treatment and will receive PV after at least 6 months of starting antiretroviral treatment
  • Arm 1
    Both groups will receive PV, the intervention is the time for vaccination (before or after starting antiretroviral treatment).
    Intervention: Biological: 23-valent pneumococcal polysaccharide vaccine
  • Placebo Comparator: Arm 2
    Arm 2 will receive placebo prior to starting antiretroviral treatment and will receive PV after at least 6 months of starting antiretroviral treatment.
    Intervention: Biological: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
107
September 2012
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • HIV infected
  • CD4 count >200
  • no acute illness
  • no pneumococcal vaccination within 3 years
  • naive to treatment or if previously on treatment, no antiretroviral treatment for at least 6 months
  • willingness to start antiretroviral treatment as recommended by current guidelines

Exclusion Criteria:

  • prior pneumococcal vaccination within 3 years
  • prior AIDS diagnosis based on opportunistic disease
  • acute illness
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00706550
INDA-002-08S
No
Department of Veterans Affairs
Department of Veterans Affairs
  • Albert Einstein College of Medicine of Yeshiva University
  • Montefiore Medical Center
Principal Investigator: Maria Rodriguez-Barradas, MD Michael E DeBakey VA Medical Center
Department of Veterans Affairs
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP